Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $14.40 billion. The enterprise value is $12.25 billion.
Important Dates
The next confirmed earnings date is Wednesday, November 6, 2024.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 63.47 million shares outstanding. The number of shares has decreased by -0.51% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 63.47M |
| Shares Change (YoY) | -0.51% |
| Shares Change (QoQ) | -1.18% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 62.83M |
Valuation Ratios
The trailing PE ratio is 18.09 and the forward PE ratio is 21.52.
| PE Ratio | 18.09 |
| Forward PE | 21.52 |
| PS Ratio | n/a |
| Forward PS | 0.65 |
| PB Ratio | n/a |
| P/FCF Ratio | 15.11 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 13.19, with an EV/FCF ratio of 12.86.
| EV / Earnings | 15.39 |
| EV / Sales | 4.48 |
| EV / EBITDA | 13.19 |
| EV / EBIT | 13.76 |
| EV / FCF | 12.86 |
Financial Position
The company has a current ratio of 5.03, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.03 |
| Quick Ratio | 5.02 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.16 |
| Debt / FCF | 0.15 |
| Interest Coverage | 176.94 |
Financial Efficiency
Return on equity (ROE) is 18.55% and return on invested capital (ROIC) is 12.58%.
| Return on Equity (ROE) | 18.55% |
| Return on Assets (ROA) | 10.97% |
| Return on Capital (ROIC) | 12.58% |
| Revenue Per Employee | $1.24M |
| Profits Per Employee | $361,140 |
| Employee Count | 2,204 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 13.33 |
Taxes
In the past 12 months, Genmab has paid $284.47 million in taxes.
| Income Tax | 284.47M |
| Effective Tax Rate | 26.33% |
Stock Price Statistics
The stock price has decreased by -23.14% in the last 52 weeks. The beta is 0.86, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -23.14% |
| 50-Day Moving Average | 24.68 |
| 200-Day Moving Average | 27.29 |
| Relative Strength Index (RSI) | 33.99 |
| Average Volume (20 Days) | 1,422,763 |
Short Selling Information
| Short Interest | 1.90M |
| Short Previous Month | 2.26M |
| Short % of Shares Out | 0.30% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.10 |
Income Statement
In the last 12 months, Genmab had revenue of $2.73 billion and earned $795.95 million in profits. Earnings per share was $12.13.
| Revenue | 2.73B |
| Gross Profit | 2.65B |
| Operating Income | 889.77M |
| Pretax Income | 1.09B |
| Net Income | 795.95M |
| EBITDA | 928.56M |
| EBIT | 889.77M |
| Earnings Per Share (EPS) | $12.13 |
Full Income StatementBalance Sheet
The company has $2.26 billion in cash and $146.40 million in debt, giving a net cash position of $2.11 billion or $33.31 per share.
| Cash & Cash Equivalents | 2.26B |
| Total Debt | 146.40M |
| Net Cash | 2.11B |
| Net Cash Per Share | $33.31 |
| Equity (Book Value) | 4.45B |
| Book Value Per Share | 70.11 |
| Working Capital | 2.52B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $967.64 million and capital expenditures -$31.61 million, giving a free cash flow of $952.60 million.
| Operating Cash Flow | 967.64M |
| Capital Expenditures | -31.61M |
| Free Cash Flow | 952.60M |
| FCF Per Share | $15.01 |
Full Cash Flow StatementMargins
Gross margin is 96.95%, with operating and profit margins of 32.57% and 29.13%.
| Gross Margin | 96.95% |
| Operating Margin | 32.57% |
| Pretax Margin | 39.55% |
| Profit Margin | 29.13% |
| EBITDA Margin | 33.99% |
| EBIT Margin | 32.57% |
| FCF Margin | 35.02% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.51% |
| Shareholder Yield | 0.51% |
| Earnings Yield | 5.53% |
| FCF Yield | 6.62% |
Dividend DetailsAnalyst Forecast
The average price target for Genmab is $43.00, which is 90.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $43.00 |
| Price Target Difference | 90.56% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 17.83% |
| EPS Growth Forecast (5Y) | 23.66% |
Stock ForecastsStock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 13.43 and a Piotroski F-Score of 6.
| Altman Z-Score | 13.43 |
| Piotroski F-Score | 6 |